Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: A single-arm, multicenter, prospective study
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 21 (2) , 106-112
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-AnalysisJournal of Investigative Surgery, 2018
- Sirolimus Use in Liver Transplant Recipients With Hepatocellular CarcinomaTransplantation, 2016
- mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in MiceGastroenterology, 2015
- Challenges to Liver Transplantation and Strategies to Improve OutcomesGastroenterology, 2015
- Current and future treatments for hepatocellular carcinomaWorld Journal of Gastroenterology, 2015
- mTOR, Cancer and TransplantationAmerican Journal of Transplantation, 2008
- Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin InhibitorsAnnals of Surgery, 2008
- Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinomaJournal of Hepatology, 2007
- Rho-Associated Kinase Inhibitor Reduces Tumor Recurrence After Liver Transplantation in a Rat Hepatoma ModelAmerican Journal of Transplantation, 2007
- EFFECT OF SYSTEMIC CYCLOSPORINE ON TUMOR RECURRENCE AFTER LIVER TRANSPLANTATION IN A MODEL OF HEPATOCELLULAR CARCINOMA1Transplantation, 1999